Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis
Go back to Keenova Announces Positive Phase 3 Results in Clinical Trial of XIAFLEX® (collagenase clostridium histolyticum) for Treating Plantar Fibromatosis| MALLINCKRODT PUBLIC LIMITED COMPANY (NYSE: MNK) | Delayed: 0.34 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.34 | 52 Week High | $85.83 | |||
| Open | $30.62 | 52 Week Low | $50.90 | |||
| Day High | $0.34 | P/E | 0.34 | |||
| Day Low | $0.34 | EPS | $1.00 | |||
| Volume | 84 | |||||
